Key Oncologics to Market Eligard™ in South Africa

By Business Review Editor

Pharma Deals Review: Vol 2002 Issue 28 (Table of Contents)

Published: 2 Sep-2002

DOI: 10.3833/pdr.v2002.i28.1015     ISSN: 1756-7874

Section: Distribution & Marketing



Atrix Laboratories signed an agreement providing Key Oncologics with the South African marketing rights for its Eligard™ (injectable leuprolide acetate suspension) prostate cancer products...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details